Smart pill tech targets HIV treatment gaps
NCT ID NCT06480578
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a system that uses a special pill bottle to track when HIV medication is taken. If doses are missed, the system alerts a care team to help address problems like food or housing issues. The goal is to help 110 adults in Los Angeles stick to their HIV treatment and improve their health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. HIV-infected individuals in HIV care 2. Greater than 17 years of age 3. Demonstrated ability to take co-encapsulated ARVs at the time of screening 4. Able to provide informed consent 5. Receiving ART with sub-optimal adherence estimated by patient (self-reports \< 90% adherence over last 28 days) or treating clinician \[e.g., based on gaps in treatment (e.g. missed appointments) or viral load elevations within 6 months\], or at high risk for sub-optimal adherence, or with known challenges with SBDOH (e.g. unstable housing, substance use disorder, and poverty 6. Currently receiving antiretroviral treatment that includes one of the following: * TDF/FTC (Truvada) * TAF/FTC (Descovy) * EFV/FTC/TDF (Atripla) * ABC/3TC (Epzicom) * DTG/ABC/3TC (Triumeq) * RPV/TAF/FTC (Odefsey) * EVG/c/FTC/TAF (Genvoya) * BIC/FTC/TAF (Biktarvy) 7. For participants of reproductive potential, negative serum or urine pregnancy test with a sensitivity of ≤25 mIU/mL at screening. This will be repeated again at study entry. NOTE: Participants are considered to be NOT of reproductive potential if: 1. participants have had amenorrhea for at least 12 consecutive months prior to study entry (i.e., who have had no menses within 12 months prior to study entry), and have a documented FSH \>40 IU/mL; OR 2. an FSH level is not available, but participants have had 24 consecutive months of amenorrhea (in the absence of medications known to induce amenorrhea); OR 3. participants report having undergone surgical sterilization (e.g., hysterectomy, or bilateral oophorectomy, or bilateral tubal ligation/hysteroscopic tubal occlusion). Exclusion Criteria: 1. Inability to follow the study procedures manifested during the intake, as evidenced by mental confusion, disorganization, intoxication, withdrawal, risky or threatening behavior 2. Pregnancy (Evaluated during the screening visit through a pregnancy test.)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Lundquist
RECRUITINGLos Angeles, California, 90502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Once-Daily HIV pill with food match Twice-Daily dosing during TB treatment?
- Four weeks vs twelve weeks: can a shorter TB prevention course work?
- Can a phone app keep young people with HIV engaged in care?
- Can paying home visiting agencies for extra services help High-Risk moms and babies?
- Massive Real-World database aims to map how chronic diseases interact
- Can a Pharmacist's talk help COPD patients breathe easier and spend less?